New Dual Agonist Weight Loss Injection Impressive, But Early Days

The 'bottom line' is that this potential new anti-obesity/diabetes drug is 'very promising, but [it is] still a little early to say where it ultimately will go,' says one obesity expert.

Related Keywords

Colorado ,United States ,Dallas ,Texas ,University Of Texas Southwestern Medical Center ,Julio Rosenstock ,Dan Bessesen ,Zealand Pharma ,University Of Colorado ,Boehringer Ingelheim ,Division Of Endocrinology ,Obesity Society ,Novo Nordisk ,Texas Southwestern Medical Center ,Still Early Days ,Medscape Medical News ,Results Presented ,Obesity ,Bese ,Weight Loss ,Weight Management ,Body Mass Index Bmi ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Endocrinology ,Ndocrine System ,